In recent years, many seeds of innovative new drugs have been created by academia and venture companies. These are co-developed, manufactured and launched in the world under the collaboration with pharmaceutical companies. The development of COVID-19 vaccines is an example. On the other hand, in Japan, there are various challenges such as the cultivation of entrepreneurs, the investment by venture capitals, and bridging the gap between pharmaceutical and venture companies. As a result, there is concern that the drug discovery capabilities in Japan will decline. Last year, the Japanese government released the Japanese Policy Vision 2021 for the Pharmaceutical Industry, which shows the vision and direction of the pharmaceutical industry policy. In addition to focusing on human resources, science technology and innovation, startups, and digital transformation (DX) as priority focus areas, the government declares that it will strengthen Japan's drug discovery capabilities. In order for Japan to continue to be a country that creates new drugs, and to achieve “the Extension of Healthy Life Expectancy of the People”, “Economic Growth”, and “Ensuring security”, industry, academia, and government will work together to build an ecosystem that promotes organic collaboration among various players in it.